NKTX News and Press, Nkarta Inc.

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sp...

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...

2024-07-01 10:20:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in...

Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...

2024-06-26 15:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today announced that translational immunology expert George Vratsanos, M.D., FACR, is joining its board o...

2024-06-09 09:44:11 ET Summary Cullinan Therapeutics, Inc. has seen a recent pullback in its shares, but they are still up 50% since mid-April after rebranding and focusing on autoimmune diseases. The company's lead asset is zipalertinib, an oral EGFR inhibitor being evaluated in ...

2024-06-06 18:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-25 02:20:02 ET Summary Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, provid...

2024-05-23 11:48:35 ET Summary Nkarta, Inc. has raised $240.1 million through a stock offering, strengthening its cash position and extending its cash runway to 2027. The company's stock has been trending down, but there are signs of recovery, with a 6.4% increase in share price. ...